Status:
COMPLETED
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Lead Sponsor:
Institut Bergonié
Conditions:
Muscle Invasive Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment deci...
Detailed Description
Background: Bladder cancer is the second most frequent genito-urinary cancer, and the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Curative tr...
Eligibility Criteria
Inclusion
- Diagnosis of Muscle Invasive Urothelial Carcinoma of the bladder (classified at least pT2 on TURB)
- Diagnosis between January 2005 and December 2017
- PET CT done during initial assessment before surgery (at the time of diagnosis and/or after neoadjuvant chemotherapy)
- Management of cancer at Institut Bergonié or at Bordeaux University Hospital
- Previous treatment for Non Muscle Invasive Bladder Cancer allowed
Exclusion
- Management of cancer outside of Institut Bergonié or Bordeaux University Hospital
- No PET CT done during initial assessment (before surgery)
- Rare pathological type of bladder cancer without urothelial carcinoma (epidermoid carcinoma, neuro-endocrine carcinoma, …)
- Extra-vesical urothelial carcinoma
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2019
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04053101
Start Date
April 1 2017
End Date
August 31 2019
Last Update
September 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France, 33076
2
Institut Bergonie
Bordeaux, France, 33076